We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), ... Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets. Show more
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities...
Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder...
取締役会は全会一致で、シノバック株主に対し、買付提案に基づく株式の買付に 応じない よう勧告する (ビジネスワイヤ) -- 中国のバイオ医薬品におけるリーディングプロバイダーであるシノバック・バイオテ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
4 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
12 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
26 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
52 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
156 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
260 | 0 | 0 | 6.47 | 6.47 | 6.47 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions